Moleculin Biotech Completes MIRACLE Trial Part A Dosing
Moleculin Biotech completed dosing in Part A of its pivotal MIRACLE trial of AnnAraC for relapsed or refractory AML. Comprehensive data are expected in Q1 2027.
Moleculin Biotech completed dosing in Part A of its pivotal MIRACLE trial of AnnAraC for relapsed or refractory AML. Comprehensive data are expected in Q1 2027.